PRISM BioLab Co.,LTD(206A) News

PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement

[Summary] Non-consolidated Financial Results for the Three Months of the Fiscal Year Ending September 30, 2026 (Under Japanese GAAP)

PRISM BioLab, Oct-Dec (1Q) Ordinary Profit Loss Widens

Phase 1 clinical research results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in ESMO OPEN

Nonclinical research results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in Clinical Cancer Research

PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets

PRISM BioLab, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.

[Summary] Financial Results for the Year

PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.

Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress

Notice Regarding the Termination of the Collaboration & License Option Agreement with Servier

PRISM BioLab, Oct-Jun (Cumulative 3Q) Ordinary Profit Loss Widens, Apr-Jun Ordinary Profit Loss Widens

Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO(American Society of Clinical Oncology) Annual Meeting

PRISM BioLab, First Half Ordinary Profit Loss Widens, Jan-Mar Ordinary Profit Loss Widens

PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug

PRISM BioLab, Oct-Dec (1Q) Ordinary Profit Loss Widens

PRISM BioLab Co.,LTD, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.